Welcome to our dedicated page for QIAGEN N.V. SEC filings (Ticker: QGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on QIAGEN N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into QIAGEN N.V.'s regulatory disclosures and financial reporting.
QIAGEN N.V. reported second‑quarter 2026 results under U.S. GAAP. Net sales were $535,040 thousand for the three months ended June 30, 2026, versus $533,540 thousand a year earlier. Quarterly net income was $103,401 thousand, with basic and diluted earnings per common share of $0.50, compared with $0.44 in 2025. For the first six months, net sales were $1,027,360 thousand and net income $171,444 thousand, with diluted EPS of $0.82.
Consumables and related revenues contributed $483,531 thousand in Q2 2026, while instruments contributed $51,509 thousand. As of June 30, 2026, cash and cash equivalents totaled $768,500 thousand, total assets $5,889,202 thousand, total equity $3,357,740 thousand, and total long‑term debt $1,643,622 thousand. Net cash provided by operating activities was $301,319 thousand for the six‑month period.
In January 2026, the company executed a $496.7 million synthetic share repurchase via capital repayment and reverse stock split, reducing outstanding shares by 10.9 million, or 5.0%. Shareholders also approved a $0.35 per‑share cash dividend for 2026, totaling $72.3 million. Convertible notes due 2027, 2031 and 2032 remained outstanding with no contingent conversion conditions triggered, and committed credit facilities were undrawn.
QIAGEN N.V. reported Q2 2026 net sales of $535 million, unchanged year-on-year on a reported and constant exchange rate (CER) basis, but ahead of its outlook for an about 2% CER decline. Growth pillars delivered about 5% CER sales growth, led by Sample technologies, QIAcuity and QIAGEN Digital Insights, while lower U.S. immigration testing weighed on QuantiFERON and QIAstat-Dx faced tough respiratory testing comparisons.
Profitability remained high. GAAP operating income increased to $132 million and net income to $103 million, with diluted EPS of $0.50 versus $0.44 a year earlier. Adjusted operating income was $157 million, for a 29.4% margin, and adjusted diluted EPS was $0.62, above the at-least $0.60 CER outlook.
Cash generation stayed solid. Net cash from operating activities was $301 million in the first half of 2026, matching H1 2025, and free cash flow was $212 million. Cash, cash equivalents and short-term investments totaled $0.8 billion at June 30, 2026, down from $1.1 billion at year-end 2025 after a $500 million synthetic share repurchase and a roughly $72 million dividend, which was increased 40% per share. The leverage ratio rose to 1.1x net debt to adjusted EBITDA.
Guidance and strategy were reaffirmed. The company maintained its 2026 outlook for net sales growth of about 1–2% CER and adjusted diluted EPS of at least $2.43 CER, and guided Q3 2026 net sales up about 1–2% CER with adjusted diluted EPS of at least $0.62 CER, supported by ongoing product launches and AI-enabled initiatives.
QIAGEN N.V. is convening its 2026 Annual General Meeting on June 24, 2026 in Venlo, with a record date of May 27, 2026. Shareholders will vote on adopting the 2025 Annual Accounts, an advisory 2025 remuneration report, and a proposed cash dividend of $0.35 per ordinary share, totaling approximately $72 million payable July 14, 2026.
The agenda includes re‑appointing eight Supervisory Directors and two Managing Directors, updating the Managing Board Remuneration Policy to add relative TSR to long‑term incentives and raise variable pay caps (STI maximum from 125% to 135% of fixed pay; LTI target from 300% to 400%), and reappointing EY as financial auditor and sustainability assurance provider for 2026.
Shareholders are also asked to authorize the Supervisory Board to issue up to 10% of issued share capital and restrict pre‑emptive rights, and to authorize the Managing Board to repurchase up to 10% of shares for 18 months. A further resolution would grant discretionary rights to implement a synthetic share repurchase via capital repayment of up to $200 million, including related share consolidation and later cancellation of treasury and fractional shares.
Massachusetts Financial Services Company amended its Schedule 13G to report beneficial ownership of 12,447,526 shares of QIAGEN N.V. common stock, representing 6.0%. The filing states MFS has sole power to vote 11,469,431 shares and sole dispositive power over 12,447,526 shares. The amendment is signed by the Compliance Director on 06/05/2026.
QIAGEN N.V. reported U.S. GAAP results for the quarter ended March 31, 2026. Net sales were $492.3 million, slightly above $483.5 million a year earlier, driven mainly by consumables. Net income fell to $68.0 million from $90.8 million, with diluted EPS at $0.33 versus $0.41.
Higher operating expenses, including $32.2 million of restructuring, acquisition, integration and other costs, reduced income from operations to $84.4 million from $115.3 million. Operating cash flow was $100.6 million, down from $139.7 million, while cash and cash equivalents declined to $646.3 million.
In January 2026, QIAGEN completed a $496.7 million synthetic share repurchase via capital repayment and reverse split, reducing outstanding shares by 10.9 million, or 5.0%. Long-term debt remained substantial at $1.65 billion, mainly convertible notes and German private placements.
QIAGEN N.V. reported Q1 2026 results showing modest sales growth but weaker earnings and a lower outlook. Net sales were $492 million, up 2% reported but down 1% at constant exchange rates. GAAP net income fell to $68 million, with diluted EPS declining to $0.33 from $0.41.
Adjusted diluted EPS was $0.54, slightly below $0.55 a year earlier, with an adjusted operating margin of 27.4% versus 29.8%. Growth pillars such as Sample technologies, QIAcuity and QIAGEN Digital Insights expanded, but QuantiFERON sales declined 5% at constant exchange rates due to sharply lower immigration testing demand.
Free cash flow dropped to $53.7 million from $95.8 million as operating cash flow declined and capital investments increased. QIAGEN cut its full-year 2026 guidance to 1–2% net sales growth at constant exchange rates and at least $2.43 adjusted diluted EPS, down from prior targets of at least 5% CER sales growth and at least $2.50 EPS.
QIAGEN N.V. released preliminary Q1 2026 results and cut its full-year 2026 outlook. Preliminary net sales were $492 million, up 2% reported but down 1% at constant exchange rates, below the prior goal for at least 1% CER growth. Adjusted diluted EPS are expected at $0.54, in line with the outlook, reflecting continued profitability.
The company’s growth pillars performed well: Sample technologies grew 9% CER to $170 million, QIAcuity digital PCR delivered double-digit CER gains, and QIAGEN Digital Insights posted solid single-digit growth. However, QuantiFERON sales fell 5% CER to $113 million, mainly from a sharp drop in immigration testing demand, and U.S. Life Sciences customers remained cautious.
QIAGEN now targets full-year 2026 net sales growth of about 1–2% CER instead of at least 5% CER, and adjusted diluted EPS of at least $2.43 CER, down from at least $2.50 CER. Management expects stronger trends in the second half of 2026 as portfolio headwinds ease and new products, including the Parse acquisition, contribute more.
QIAGEN N.V. reports 2025 net sales of $2,090.0 million, up from $1,978.2 million in 2024, driven mainly by consumables and related revenues, which made up 90% of sales. Instruments contributed the remaining 10%.
The Americas generated $1,086.5 million of net sales, with Europe, Middle East and Africa at $712.8 million and Asia Pacific, Japan and Rest of World at $290.7 million. As of December 31, 2025, the company had 5,654 employees and 216,920,735 outstanding common shares.
QIAGEN focuses on five growth pillars, including QIAcuity digital PCR, QIAstat‑Dx syndromic testing, QuantiFERON and its Digital Insights bioinformatics portfolio, aiming to grow pillar sales from $1.5 billion in 2025 to about $2 billion by 2028. The company serves more than 500,000 customers in molecular diagnostics and Life Sciences across over 160 countries, emphasizes ESG integration, and highlights detailed enterprise risk management around competition, supply chain, leadership succession and cyber security.
Wellington Management Group and affiliates report a 6.5% beneficial ownership stake in Qiagen N.V. common stock on Schedule 13G/A (Amendment No. 3). The group reports beneficial ownership of 14,137,799 shares as of the event date, with all voting and dispositive power held on a shared basis.
Within the complex, Wellington Management Company LLP reports shared voting power over 12,155,318 shares and shared dispositive power over 12,416,628 shares, representing 5.7% of the class. The filing states that the securities are owned of record by clients of Wellington investment advisers and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Qiagen.